CJC-1295 (no DAC) / Ipamorelin Protocol

A combination protocol using CJC-1295 without DAC (also known as Mod GRF 1-29) and Ipamorelin through complementary receptor mechanisms. CJC-1295 without DAC has a short half-life of 30 minutes to 2 hours, enabling pulsatile GH release that mimics natural physiology. Ipamorelin provides selective GH release without affecting cortisol, ACTH, or prolactin. Note: This protocol uses the no-DAC version specifically for pulsatile release patterns.

• Enhanced protein synthesis
• Improved recovery
• Lean mass preservation

Dual-pathway GH optimization through complementary mechanisms. CJC-1295 without DAC (Mod GRF 1-29) and Ipamorelin both have short half-lives (30 min-2 hours), producing synergistic pulsatile GH spikes that mimic natural physiology without cortisol effects.

CJC-1295 without DAC (Mod GRF 1-29) stimulates GHRH receptors on pituitary somatotrophs, triggering cAMP/PKA-mediated GH synthesis with a short 30-minute to 2-hour half-life. Ipamorelin selectively activates ghrelin receptors (GHSR1a) via Gq/11-linked calcium signaling without affecting ACTH or cortisol pathways. Together, the dual-pathway activation produces amplified, pulsatile GH spikes. Note: Combination benefits are theoretically sound but lack direct clinical validation.

Research protocols from published literature — not dosing recommendations.

• MK-677 — Monitor Combination: Both affect GH pathways. Monitor for excessive GH elevation and potential insulin sensitivity changes with combined use.
• BPC-157 — Compatible: No known interactions. Different mechanisms - GH optimization versus direct tissue repair signaling.
• Insulin — Monitor Combination: Growth hormone affects insulin sensitivity. Diabetic users require blood glucose monitoring and potential insulin dose adjustments.
• Synthetic HGH — Avoid Combination: Redundant mechanisms may cause excessive GH levels and suppress natural pulsatile release patterns.
• Thyroid Medications — Requires Timing: Space thyroid medications 4+ hours from GH secretagogues due to potential absorption and metabolic interactions.
• Corticosteroids — Use Caution: Corticosteroids can blunt GH response. May require higher doses or alternative timing when used together.

Supplies:

• Bacteriostatic water (BAC water)
• Insulin syringes (29-31 gauge)
• Alcohol swabs
• CJC-1295 / Ipamorelin lyophilized powder vial(s)

1. 1Allow vial(s) to reach room temperature (15-20 minutes)
2. 2Clean vial top(s) with alcohol swab and allow to dry
3. 3Calculate required bacteriostatic water volume using the calculator below
4. 4Draw calculated volume of bacteriostatic water into syringe
5. 5Inject water slowly down the inside wall of the vial (never directly onto powder)
6. 6Gently swirl until powder completely dissolves (never shake)
7. 7Solution should be clear - discard if cloudy or contains particles
8. 8Store reconstituted solution in refrigerator at 2-8°C
9. 9Administer 2-3 hours after last meal, 30-60 minutes before bed
10. 10Rotate subcutaneous injection sites (abdomen, thigh, upper arm) to prevent tissue issues

Week 1-2: Improved sleep depth and quality. Some users report more vivid dreams. Week 3-4: Enhanced recovery from exercise. Reduced muscle soreness and improved energy. Week 6-8: Gradual body composition changes. Improved skin quality and general well-being. Week 8-12: Optimized benefits if protocol is effective. Individual responses vary significantly. Post-cycle: Some benefits may persist for several weeks due to improved sleep and recovery patterns.

CRITICAL: Test individual peptides separately before using blended protocols if possible. NOTE: No clinical trials have validated specific combination benefits or safety profiles. Use only pharmaceutical-grade peptides with verified certificates of analysis. Monitor blood glucose if diabetic - growth hormone can affect insulin sensitivity. Start with conservative doses (200mcg each) to assess individual tolerance. Discontinue if adverse reactions occur and consider separate testing to identify source. Maintain injection site rotation to prevent lipodystrophy or tissue damage. Regular bloodwork recommended to monitor IGF-1 levels and overall health markers.

CRITICAL: Test individual peptides separately before using blended protocols if possible. NOTE: No clinical trials have validated specific combination benefits or safety profiles. Use only pharmaceutical-grade peptides with verified certificates of analysis. Monitor blood glucose if diabetic - growth hormone can affect insulin sensitivity. Start with conservative doses (200mcg each) to assess individual tolerance. Discontinue if adverse reactions occur and consider separate testing to identify source. Maintain injection site rotation to prevent lipodystrophy or tissue damage. Regular bloodwork recommended to monitor IGF-1 levels and overall health markers.